ABBVIE, INC. for ABBVIE INC.
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018 Draft legislation relating to economic activity in Puerto Rico International tax issues, including OECD digital taxation work program
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL BACHNER | — |
| STEPHEN SCANGO | — |
Copyright/Patent/Trademark CPT
H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements H.R. 3991, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019 H.R. 5133, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 Biopharmaceutical innovation and patent policy issues S. 1416, Affordable Prescriptions for Patients Act of 2019 - Provisions related to prescription drug patents Patent litigation reform issues and issues related to post-grant proceedings at the PTO Value of intellectual property
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL BACHNER | — |
| BINTA BEARD | — |
| STEPHEN SCANGO | — |
Budget/Appropriations BUD
H.R. 2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Bill 2020 - HHS provisions related to prescription drugs FY 2020 Omnibus Appropriations Bill - Provisions relating to biopharmaceutical products
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL BACHNER | — |
| BINTA BEARD | — |
| STEPHEN SCANGO | — |
Health Issues HCR
H.R. 3, Lower Drug Costs Now Act of 2019 - Provisions related to non-interference, International Pricing Index Model and Medicare Part D H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 2113, Prescription Drug STAR Act - Provisions related to transparency of prescription drug pricing S.1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues H.R. 6201, Families First Coronavirus Response Act - provisions related to health care 340B drug discount program policy issues Drug cost and pricing policy issues Transparency policy issues Patient affordability issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL BACHNER | — |
| BINTA BEARD | — |
| STEPHEN SCANGO | — |
Medicare/Medicaid MMM
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Medicare Part D, drug pricing negotiation and march-in rights S. 475, RxCAP Act of 2019 - Provisions related to Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference, out of pocket cap and rebates policy issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D Medicaid policy issues including rebates policy and average manufacture price (AMP) caps CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2021; Notice Requirement for Non-Federal Governmental Plans proposed rule
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL BACHNER | — |
| BINTA BEARD | — |
| STEPHEN SCANGO | — |
Trade (domestic/foreign) TRD
USMCA and related policy issues Policy proposals impacting biopharmaceutical supply chain
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL BACHNER | — |
| STEPHEN SCANGO | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.